Skip to main content
. Author manuscript; available in PMC: 2011 Sep 1.
Published in final edited form as: Cancer Prev Res (Phila). 2010 Jul 20;3(9):1141–1147. doi: 10.1158/1940-6207.CAPR-10-0005

Figure 7.

Figure 7

Comparison of tumors from mice treated with control or vandetanib chow (weeks 1–15) or DC101 injection (weeks 11–15). There are no significant changes in tumor histology. Tumor microvessels demonstrated by CD34 immunostaining are reduced in both vadetanib and DC101 treated mice, more completely in the latter. pEGFR immunostaining is abolished in vandetanib treated tumors, but not control or DC101 treated. pVEGFR2 immunostaining is reduced in both vandetanib and DC101 treated tumors, more completely in the former.